HST Global, Inc. (HSTC)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 98.31 Thousand USD | 29.24% |
| 2022 | 76.07 Thousand USD | 38.13% |
| 2021 | 55.07 Thousand USD | 114.51% |
| 2020 | 25.67 Thousand USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 1.37 Million USD | 1.76% |
| 2017 | 1.35 Million USD | 2.25% |
| 2016 | 1.32 Million USD | 1.71% |
| 2015 | 1.29 Million USD | 1.75% |
| 2014 | 1.27 Million USD | 2.17% |
| 2013 | 1.25 Million USD | 2.46% |
| 2012 | 1.22 Million USD | 12.96% |
| 2011 | 1.08 Million USD | 11.34% |
| 2010 | 970 Thousand USD | 223.33% |
| 2009 | 300 Thousand USD | 200.0% |
| 2008 | 100 Thousand USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 1.69 Million USD | 164.43% |
| 2005 | 640 Thousand USD | 213.73% |
| 2004 | 204 Thousand USD | 2.0% |
| 2003 | 200 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 20 Thousand USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 540 Thousand USD | -70.17% |
| 1997 | 1.81 Million USD | 0.56% |
| 1996 | 1.8 Million USD | -55.0% |
| 1995 | 4 Million USD | 21.21% |
| 1994 | 3.3 Million USD | 17.86% |
| 1993 | 2.8 Million USD | 64.71% |
| 1992 | 1.7 Million USD | -22.73% |
| 1991 | 2.2 Million USD | 175.0% |
| 1990 | 800 Thousand USD | 33.33% |
| 1989 | 600 Thousand USD | 50.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 21.6 Thousand USD | -78.47% |
| 2024 Q1 | 100.31 Thousand USD | 2.03% |
| 2023 Q3 | 93.31 Thousand USD | 4.53% |
| 2023 FY | 98.31 Thousand USD | 29.24% |
| 2023 Q2 | 89.27 Thousand USD | 6.18% |
| 2023 Q4 | 98.31 Thousand USD | 5.36% |
| 2023 Q1 | 84.07 Thousand USD | 10.52% |
| 2022 Q1 | 62.07 Thousand USD | 12.71% |
| 2022 Q4 | 76.07 Thousand USD | 6.29% |
| 2022 Q3 | 71.57 Thousand USD | 6.71% |
| 2022 Q2 | 67.07 Thousand USD | 8.05% |
| 2022 FY | 76.07 Thousand USD | 38.13% |
| 2021 Q1 | 31.09 Thousand USD | 21.12% |
| 2021 Q2 | 46.77 Thousand USD | 50.41% |
| 2021 FY | 55.07 Thousand USD | 114.51% |
| 2021 Q3 | 50.77 Thousand USD | 8.55% |
| 2021 Q4 | 55.07 Thousand USD | 8.47% |
| 2020 FY | 25.67 Thousand USD | 0.0% |
| 2020 Q4 | 25.67 Thousand USD | 0.0% |
| 2020 Q1 | 5203.00 USD | 0.0% |
| 2020 Q2 | 21.67 Thousand USD | 316.61% |
| 2020 Q3 | 25.67 Thousand USD | 18.45% |
| 2019 FY | - USD | -100.0% |
| 2019 Q1 | 1.37 Million USD | 0.01% |
| 2019 Q2 | 675 Thousand USD | -50.92% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q4 | 1.37 Million USD | 0.44% |
| 2018 FY | 1.37 Million USD | 1.76% |
| 2018 Q1 | 1.36 Million USD | 0.72% |
| 2018 Q2 | 1.36 Million USD | 0.32% |
| 2018 Q3 | 1.36 Million USD | 0.26% |
| 2017 Q1 | 1.32 Million USD | 0.62% |
| 2017 Q2 | 1.33 Million USD | 0.34% |
| 2017 Q3 | 1.34 Million USD | 0.75% |
| 2017 Q4 | 1.35 Million USD | 0.52% |
| 2017 FY | 1.35 Million USD | 2.25% |
| 2016 Q4 | 1.32 Million USD | 0.36% |
| 2016 Q2 | 1.31 Million USD | 1.07% |
| 2016 FY | 1.32 Million USD | 1.71% |
| 2016 Q1 | 1.29 Million USD | 0.0% |
| 2016 Q3 | 1.31 Million USD | 0.27% |
| 2015 Q1 | 1.28 Million USD | 0.68% |
| 2015 Q4 | 1.29 Million USD | 0.35% |
| 2015 FY | 1.29 Million USD | 1.75% |
| 2015 Q3 | 1.29 Million USD | 0.39% |
| 2015 Q2 | 1.28 Million USD | 0.33% |
| 2014 Q4 | 1.27 Million USD | 0.16% |
| 2014 Q1 | 1.26 Million USD | 0.8% |
| 2014 FY | 1.27 Million USD | 2.17% |
| 2014 Q3 | 1.27 Million USD | 0.55% |
| 2014 Q2 | 1.26 Million USD | 0.64% |
| 2013 Q3 | 1.25 Million USD | 0.81% |
| 2013 FY | 1.25 Million USD | 2.46% |
| 2013 Q4 | 1.25 Million USD | 0.0% |
| 2013 Q2 | 1.24 Million USD | 1.64% |
| 2013 Q1 | 1.22 Million USD | 0.0% |
| 2012 Q1 | 1.11 Million USD | -3.48% |
| 2012 Q4 | 1.22 Million USD | 4.27% |
| 2012 Q2 | 1.13 Million USD | 1.8% |
| 2012 FY | 1.22 Million USD | 12.96% |
| 2012 Q3 | 1.17 Million USD | 3.54% |
| 2011 FY | 1.08 Million USD | 11.34% |
| 2011 Q1 | 980 Thousand USD | 1.03% |
| 2011 Q2 | 1.01 Million USD | 3.06% |
| 2011 Q3 | 1.03 Million USD | 1.98% |
| 2011 Q4 | 1.15 Million USD | 11.65% |
| 2010 Q4 | 970 Thousand USD | 16.87% |
| 2010 FY | 970 Thousand USD | 223.33% |
| 2010 Q3 | 830 Thousand USD | 9.21% |
| 2010 Q2 | 760 Thousand USD | 13.43% |
| 2010 Q1 | 670 Thousand USD | 123.33% |
| 2009 Q2 | 260 Thousand USD | 44.44% |
| 2009 Q4 | 300 Thousand USD | 200.0% |
| 2009 FY | 300 Thousand USD | 200.0% |
| 2009 Q1 | 180 Thousand USD | 80.0% |
| 2009 Q3 | 100 Thousand USD | -61.54% |
| 2008 Q4 | 100 Thousand USD | 0.0% |
| 2008 FY | 100 Thousand USD | 0.0% |
| 2008 Q1 | 70 Thousand USD | 75.0% |
| 2008 Q2 | 100 Thousand USD | 42.86% |
| 2008 Q3 | 100 Thousand USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 Q1 | 1.85 Million USD | 9.54% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | 40 Thousand USD | -50.0% |
| 2007 Q3 | 80 Thousand USD | 0.0% |
| 2006 Q2 | 2.63 Million USD | 998.26% |
| 2006 Q1 | 240 Thousand USD | -72.73% |
| 2006 Q4 | 1.69 Million USD | -40.09% |
| 2006 FY | 1.69 Million USD | 164.43% |
| 2006 Q3 | 2.82 Million USD | 7.17% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | 640 Thousand USD | 213.73% |
| 2005 Q1 | 224 Thousand USD | 9.8% |
| 2005 Q2 | 224 Thousand USD | 0.0% |
| 2005 Q4 | 880 Thousand USD | 0.0% |
| 2004 Q4 | 204 Thousand USD | -5.99% |
| 2004 Q2 | 236.6 Thousand USD | 0.0% |
| 2004 Q1 | 236.6 Thousand USD | 18.3% |
| 2004 Q3 | 217 Thousand USD | -8.28% |
| 2004 FY | 204 Thousand USD | 2.0% |
| 2003 Q4 | 200 Thousand USD | 0.0% |
| 2003 Q1 | - USD | -100.0% |
| 2003 FY | 200 Thousand USD | 0.0% |
| 2003 Q3 | 200 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | 10 Thousand USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | 110 Thousand USD | 0.0% |
| 2001 Q4 | 10 Thousand USD | -96.67% |
| 2001 FY | - USD | -100.0% |
| 2001 Q1 | 380 Thousand USD | 0.0% |
| 2001 Q2 | 340 Thousand USD | -10.53% |
| 2001 Q3 | 300 Thousand USD | -11.76% |
| 2000 Q1 | 140 Thousand USD | 0.0% |
| 2000 Q4 | 380 Thousand USD | -24.0% |
| 2000 Q3 | 500 Thousand USD | 56.25% |
| 2000 Q2 | 320 Thousand USD | 128.57% |
| 2000 FY | 20 Thousand USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q3 | 40 Thousand USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1999 Q1 | 130 Thousand USD | -18.75% |
| 1999 Q2 | - USD | -100.0% |
| 1998 Q2 | 510 Thousand USD | -71.51% |
| 1998 Q3 | 1.01 Million USD | 98.04% |
| 1998 Q1 | 1.79 Million USD | -1.1% |
| 1998 Q4 | 160 Thousand USD | -84.16% |
| 1998 FY | 540 Thousand USD | -70.17% |
| 1997 Q2 | 2.17 Million USD | 8.5% |
| 1997 Q3 | 2.11 Million USD | -2.76% |
| 1997 Q4 | 1.81 Million USD | -14.22% |
| 1997 FY | 1.81 Million USD | 0.56% |
| 1997 Q1 | 2 Million USD | 11.11% |
| 1996 FY | 1.8 Million USD | -55.0% |
| 1996 Q1 | 3.9 Million USD | -2.5% |
| 1996 Q2 | 3.7 Million USD | -5.13% |
| 1996 Q3 | 1.7 Million USD | -54.05% |
| 1996 Q4 | 1.8 Million USD | 5.88% |
| 1995 Q4 | 4 Million USD | 8.11% |
| 1995 Q1 | 3.2 Million USD | -3.03% |
| 1995 Q2 | 3.4 Million USD | 6.25% |
| 1995 Q3 | 3.7 Million USD | 8.82% |
| 1995 FY | 4 Million USD | 21.21% |
| 1994 Q4 | 3.3 Million USD | -3.79% |
| 1994 Q1 | 3.3 Million USD | 17.86% |
| 1994 Q2 | 3.3 Million USD | 0.0% |
| 1994 Q3 | 3.43 Million USD | 3.94% |
| 1994 FY | 3.3 Million USD | 17.86% |
| 1993 Q1 | 1.5 Million USD | -11.76% |
| 1993 Q2 | 1.5 Million USD | 0.0% |
| 1993 FY | 2.8 Million USD | 64.71% |
| 1993 Q3 | 1.5 Million USD | 0.0% |
| 1993 Q4 | 2.8 Million USD | 86.67% |
| 1992 FY | 1.7 Million USD | -22.73% |
| 1992 Q1 | 1.8 Million USD | -18.18% |
| 1992 Q2 | 1.8 Million USD | 0.0% |
| 1992 Q3 | 1.6 Million USD | -11.11% |
| 1992 Q4 | 1.7 Million USD | 6.25% |
| 1991 Q2 | 600 Thousand USD | -14.29% |
| 1991 Q4 | 2.2 Million USD | 120.0% |
| 1991 FY | 2.2 Million USD | 175.0% |
| 1991 Q1 | 700 Thousand USD | -12.5% |
| 1991 Q3 | 1 Million USD | 66.67% |
| 1990 Q3 | 900 Thousand USD | 0.0% |
| 1990 FY | 800 Thousand USD | 33.33% |
| 1990 Q4 | 800 Thousand USD | -11.11% |
| 1990 Q1 | 1 Million USD | 66.67% |
| 1990 Q2 | 900 Thousand USD | -10.0% |
| 1989 Q2 | 600 Thousand USD | 0.0% |
| 1989 Q4 | 600 Thousand USD | 0.0% |
| 1989 FY | 600 Thousand USD | 50.0% |
| 1989 Q3 | 600 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.761% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 97.615% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.642% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.773% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.67% |
| Mesoblast Limited | 118.7 Million USD | 99.917% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 89.632% |
| Genus plc | 233.1 Million USD | 99.958% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 96.645% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 92.682% |
| Marizyme, Inc. | 18.71 Million USD | 99.475% |
| ContraFect Corporation | 2.88 Million USD | 96.587% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 86.891% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 27.433% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 93.202% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 95.773% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 98.262% |
| MultiCell Technologies, Inc. | 202.58 USD | -48433.419% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.829% |
| EV Biologics, Inc. | 1.49 Million USD | 93.422% |
| Q BioMed Inc. | 4.1 Million USD | 97.608% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.703% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 84.396% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 91.996% |
| Biomind Labs Inc. | 735.54 Thousand USD | 86.633% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.943% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.244% |
| Skye Bioscience, Inc. | 4.61 Million USD | 97.87% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 88.929% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 30.525% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 98.325% |
| IMV Inc. | 28.88 Million USD | 99.66% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -282.282% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 95.646% |
| GB Sciences, Inc. | 1.75 Million USD | 94.411% |
| Alpha Cognition Inc. | 1.22 Million USD | 91.944% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Halberd Corporation | 150 Thousand USD | 34.454% |
| Enzolytics Inc. | 996.33 Thousand USD | 90.132% |
| Resverlogix Corp. | 6.49 Million USD | 98.485% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 79.41% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 61.533% |
| argenx SE | 20 Million USD | 99.508% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.784% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 96.37% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -861.555% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.976% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 50.991% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 95.899% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 57.12% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.855% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 96.751% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 72.667% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.516% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 33.861% |
| BioStem Technologies, Inc. | 4.71 Million USD | 97.913% |
| ONE Bio Corp. | 19.71 Million USD | 99.501% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 60.701% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 60.47% |
| Agentix Corp. | 50 Thousand USD | -96.638% |
| LadRx Corporation | 33.6 Thousand USD | -192.564% |
| Cell Source, Inc. | 9.25 Million USD | 98.938% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 86.998% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 86.998% |
| NovAccess Global Inc. | 2.19 Million USD | 95.531% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.61% |
| Itoco Inc. | 228.37 Thousand USD | 56.949% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 53.398% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 98.027% |
| Kadimastem Ltd | 891.22 Thousand USD | 88.968% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 75.533% |
| CytoDyn Inc. | 30.07 Million USD | 99.673% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 79.698% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 72.056% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.743% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 19.74% |
| Rebus Holdings, Inc. | 310 Thousand USD | 68.284% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 97.924% |
| International Stem Cell Corporation | 4.17 Million USD | 97.647% |
| Bioxytran, Inc. | 1.92 Million USD | 94.893% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -57.53% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 95.492% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.818% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.855% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 93.679% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 63.314% |
| Neutra Corp. | 54.15 Thousand USD | -81.548% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 94.627% |
| PureTech Health plc | 25.51 Million USD | 99.615% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 91.969% |
| IXICO plc | 472.02 Thousand USD | 79.171% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.366% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.842% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.894% |